Join
Live feed
·
PRReleasevia Quantisnow
Bright Minds Biosciences Inc. logo

Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026

ByQuantisnow·Wall Street's wire, on your screen.
DRUG· Bright Minds Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DRUG (Bright Minds Biosciences Inc.) and more on Quantisnow.